Cited by 115Nanoparticle-Based Drug DeliveryTelomeres, Telomerase, and SenescenceRNA Interference and Gene Delivery

Progressive slowdown/prevention of cellular senescence by CD9-targeted delivery of rapamycin using lactose-wrapped calcium carbonate nanoparticles

Open access
Thapa, Raj Kumar, Nguyen, Hanh Thuy, Jeong, Jee-Heon, Kim, Jae Ryong, Choi, Han-Gon, Yong, Chul Soon, Kim, Jong Oh·2017·Scientific Reports

Abstract

Cellular senescence, a state of irreversible growth arrest and altered cell function, causes aging-related diseases. Hence, treatment modalities that could target aging cells would provide a robust therapeutic avenue. Herein, for the first time, we utilized CD9 receptors (overexpressed in senescent cells) for nanoparticle targeting in addition to the inherent β-galactosidase activity. In our study, CD9 monoclonal antibody-conjugated lactose-wrapped calcium carbonate nanoparticles loaded with rapamycin (CD9-Lac/CaCO 3/Rapa) were prepared for targeted rapamycin delivery to senescent cells. The nanoparticles exhibited an appropriate particle size (~130 nm) with high drug-loading capacity (~20%). In vitro drug release was enhanced in the presence of β-galactosidase suggesting potential cargo drug delivery to the senescent cells. Furthermore, CD9-Lac/CaCO 3/Rapa exhibited high uptake and anti-senescence effects (reduced β-galactosidase and p53/p21/CD9/cyclin D1 expression, reduced population doubling time, enhanced cell proliferation and migration, and prevention of cell cycle arrest) in old human dermal fibroblasts. Importantly, CD9-Lac/CaCO 3/Rapa significantly improved the proliferation capability of old cells as suggested by BrdU staining along with significant reductions in senescence-associated secretory phenotypes (IL-6 and IL-1β) (P < 0.05). Altogether, our findings suggest the potential applicability of CD9-Lac/CaCO 3/Rapa in targeted treatment of senescence.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep43299

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Rapamycin and its analogue RAD001 reduced the protumorigenic SASP, prevented senescence, impaired SASP-mediated immune recognition of oncogene-expressing cells, and improved liver dysfunction in naturally aged mice.

    “Treatment with rapamycin (and its analogue RAD001)232 attenuated the protumorigenic SASP230, prevented senescence233, impaired SASP-mediated immune recognition of oncogene-expressing cells and ameliorated liver dysfunction in naturally aged mice231.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Thapa, R. K., Nguyen, H. T., Jeong, J.-H., Kim, J. R., Choi, H.-G., Yong, C. S., & Kim, J. O.
Affiliations
  • Yeungnam University (KR)
  • Yeungnam University College (KR)
  • Hanyang University (KR)
Corresponding author
  • Kim, Jae Ryong
  • Yong, Chul Soon
  • Kim, Jong Oh
Venue
Scientific Reports
Published
2017-04-10
Volume
7
Issue
1
Pages
43299-43299
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2605847570
Cited by
115
References
39
Citations by year
2026: 6 · 2025: 15 · 2024: 21 · 2023: 10 · 2022: 19 · 2021: 9 · 2020: 14 · 2019: 9 · 2018: 8 · 2017: 4
FWCI
3.45
Type
journal article
Language
en
Open access
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Research Foundation (2015R1A5A2009124)
  • Ministry of Science, ICT and Future Planning (2015R1A2A2A01004118, 2015R1A2A2A04004806, 2015R1A5A2009124)
  • National Research Foundation of Korea (2015R1A2A2A01004118, 2015R1A2A2A04004806, 2015R1A5A2 009124, 2015R1A2A2A01004118, 2015R1A2A2A04004806)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
cellular senescence, rapamycin, calcium carbonate nanoparticles, targeted drug delivery, beta-galactosidase, dermal fibroblasts, aging, senescence-associated secretory phenotype, cell proliferation, anti-senescence therapy
MeSH terms
Antibodies, Monoclonal, Calcium Carbonate, Cells, Cultured, Fibroblasts, Humans, Lactose, Cellular Senescence, Sirolimus, Cell Proliferation, Nanoparticles, Tetraspanin 29

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review